| INTRODUCTION
Thrombocytopenia is common among critically ill patients [1] [2] [3] and platelet transfusions are often used to increase the platelet count in patients admitted to the intensive care unit (ICU). However, the effect of platelet transfusions on clinical outcomes, especially bleeding prevention, has not been well described in this population. 4 One reason is that bleeding occurrences in the ICU are dynamic and the measurement of major bleeding requires frequent, prospective assessments using population-specific measurement tools. In other patient groups such as hematology/oncology patients, the benefit of prophylactic platelet transfusions has been demonstrated in randomized trials. 5, 6 No such data are available for critically ill patients, who often receive this treatment in the context of an increased bleeding risk due to surgery of frequent invasive procedures. 7 A recent systematic review highlighted the lack of ICU-specific data and identified the urgent need for platelet transfusion studies with clinical endpoints in this population. 8 Platelet transfusions are also associated with harms, including well-accepted risks of transfusion-transmitted infection, allergic reactions, and inflammatory responses. In addition, they have been linked to the occurrence of venous thrombosis, 9 arterial thrombosis 10 and infection 11 in critically ill patients. Some studies have reported an association between platelet transfusions and mortality, but whether transfusion truly increases the risk of death or is a marker of the severity of the underlying illness is unclear. 10, 12 A better understanding of the clinical benefits and potential harms of platelet transfusions is essential to justify whether and how this common treatment should be used. 13 The primary objective of this study was to evaluate the association between platelet transfusions and major bleeding in critically ill patients. We used data from a large international thromboprophylaxis trial (PROTECT, clinicaltrials.gov NCT00182143) in which bleeding data were collected daily prospectively using an ICU-specific bleeding assessment tool. Patients were recruited from 2006 to 2010. Secondary objectives were to assess potential harms of transfusion, including thrombosis and death; factors associated with platelet transfusion administration; and platelet count increments following transfusion.
| METHODS

| Patients
We conducted an observational cohort study nested in a previous multinational, concealed, stratified, randomized, and blinded thrombo- 
Essentials
• Platelet transfusions are commonly used to treat critically ill patients with thrombocytopenia.
• Observational cohort study nested in a previous randomized trial in the intensive care unit.
• Major bleeding was not different in thrombocytopenic patients who did or did not get platelets.
• Thrombocytopenia, anemia, and anticoagulants were associated with platelet transfusion use. The ABO blood group of the recipient and donor were also recorded.
Participating centers submitted platelet transfusion records as source documents. This study was approved by the research ethics boards at each participating center.
| Statistical analysis
We compared demographic variables among patients who did and did not receive platelet transfusion(s) using the Mann-Whitney U test for continuous variables or Chi-square or Fisher's Exact test for categorical variables. We analyzed the association between prophylactic platelet transfusions and major bleeding using a multivariable Cox proportional hazards model for recurrent events, adjusted for age, treatment group in the main trial (unfractionated heparin [UFH] or dalteparin), use of antiplatelet agents, surgery, platelet count (≥150×10 9 /L; 100-149×10 9 /L; 50-99×10 9 /L; and <50×10 9 /L) and hemoglobin level. If the proportional hazards assumption did not hold for a discrete variable, it was used as a stratification variable.
We assumed that the effect of a prophylactic transfusion lasted for 5 days based on the expected survival time of transfused platelets in circulation; thus, in the model, this time-varying variable would "switch on" immediately after the transfusion and "switch off" 5 days later. We used two models to investigate the association between prophylactic platelet transfusions and major bleeding events. In the first model, patients were considered at risk from the time of ICU admission until the time of discharge from ICU or death. In the second model, patients were considered at risk from the time of admission to the time of the first major bleed, discharge from ICU, or death.
We considered similar stratified multivariate Cox regression anal- 
| Patient-level analyses
In our adjusted regression model which considered all prophylactic platelet transfusions, there was no statistically significant difference in the rate of major bleeding for patients who received prophylactic platelet transfusions (HR = 0.85, 95% CI 0.42-1.72; Table 2 ); but the effect was in the direction of bleeding avoidance. Similar results were F I G U R E 1 Patients from the PROTECT trial, a randomized thromboprophylaxis trial in critically ill patients, and platelet transfusions analyzed in this study (Table 3) ; however, the effect was in the direction of a survival advantage.
T 
| Transfusion-level analyses
For all platelet transfusions, pre-transfusion platelet counts were buffy coat (n = 58/186; 31.2%), or whole blood-derived pooled platelet concentrates (69/186; 37.1%; Table S1 ). Platelet product information was missing for 4 transfusions. Platelet transfusions were incompatible with the ABO blood group of the recipient for 30 patients (15.9%).
Factors associated with platelet transfusion administration were thrombocytopenia, especially platelet counts <50×10 Table 4) .
Of the 33 non-bleeding patients with a platelet count less than were associated with smaller platelet count increments.
| DISCUSSION
In this sub-study of a large randomized trial, we found that prophylactic platelet transfusions administered to critically ill patients with thrombocytopenia were not associated with a reduction in the risk of major bleeding compared to non-transfused thrombocytopenic patients. The number of transfused patients was small which limits the inferences one can make based on these data, and raises the possibility of spurious results including a type II error concluding that platelets do not prevent bleeding when they actually do. Indeed, the direction of the effect favored bleeding prevention, however the effect size was small, and perhaps substantially smaller than intensivists may anticipate when transfusing platelets in the ICU. This study, despite its modest sample size, is unique in that we examined bleeding outcomes after platelet transfusions in ICU patients using validated bleeding data that were collected prospectively on a daily basis. Assuming that the risk of major bleeding in non-transfused ICU patients with severe thrombocytopenia (platelets <50×10 9 /L) is ~20% 15, 19 , and the risk of major bleeding in transfused patients is ~10%, we estimated that a randomized trial of prophylactic platelet transfusions in this setting would require several thousand patients, depending on the ICU type and adjustment for covariates.
Thrombocytopenia is a common complication of critical illness with a prevalence on ICU admission of up to 64% and an incidence over the ICU stay of up to 34%. 3 The cause of thrombocytopenia in this setting is multifactorial 4 often related to bone marrow suppression from acute illness or infection, platelet consumption associated with disseminated intravascular coagulation or circulatory bypass or dilution from major fluid shifts. Rarely is a drug reaction or a primary hematological disorder the cause. ICU-acquired thrombocytopenia has been associated with clinical outcomes including major bleeding, blood transfusions, and death 1 ; however, whether platelet transfusions can mitigate the risk of these events is unclear.
In 2015, the National Heart, Lung, and Blood Institute identified several key priority research questions in the clinical practice of transfusion medicine. Among them were the safety and efficacy of prophylactic platelet transfusions before common invasive procedures and the clinical consequences of ABO matching in diverse patient groups including critical care. 13 Our study begins to address some of these issues.
We found no significant difference in the risk of major bleeding among thrombocytopenic patients who did and did not receive a platelet transfusion; however, further prospective controlled trials are needed.
We did not identify a significant association between platelet transfusions and thrombosis, although there was a trend towards harm. This finding is consistent with a previous study conducted in a similar medical-surgical ICU population, which showed that platelet transfusion increased the risk of venous thrombosis. 9 In a recent study using data from a national hospital discharge database in the United States, investigators reported that platelet transfusions were associated with an increased risk of in-hospital death in patients with thrombocytopenia due to heparin-induced thrombocytopenia and thrombotic thrombocytopenic purpura. 10 Those conditions are inherently pro-thrombotic and the study did not adjust for platelet count levels; thus, the results are not readily generalizable to a broader ICU population. In other studies, platelet transfusions were associated with an increased risk of death among patients undergoing liver transplantation 12 and cardiac surgery 20 ; however, these results derive from non-randomized data confounded by illness severity. Our results do not clearly show a survival benefit, but the confidence intervals were wide and underscore how larger studies are needed to confirm or refute any such association.
Additional findings in this study were that a single platelet transfusion episode would be expected to raise the platelet count by approximately 20×10 9 /L, which is consistent with other ICU studies. 7, 21 The platelet count increment was most pronounced within a few hours and the effect was generally short lived. The need for multiple transfusions and a high pre-transfusion platelet count (≥100×10 9 /L) were associated with a smaller platelet count increment post transfusion.
In this study, an ABO blood group incompatibility between donor and recipient was not associated with a smaller platelet count increment;
however, this analysis was underpowered. In a previous ICU study which included predominantly cardiac surgery patients, ABO incompatibility was a significant predictor of poor platelet count increment. 7 It is evident that the anticipated platelet count increment after a platelet transfusion depends on the population and the underlying cause of the thrombocytopenia.
A key strength of this study was the rigorous assessments of bleeding-the most critical outcome in platelet transfusion studies.
Unlike many other studies in this field, bleeding data were collected prospectively, on a daily basis, using a clinically useful, ICU-specific, validated bleeding tool with high inter-rater reliability. 15 We used a blinded adjudication process for all major bleeds, which demonstrated high agreement. 16 Other strengths were our analysis of the association between prophylactic platelet transfusions and major bleeding, which was adjusted for variables known to be related to this outcome. of screening for the main trial were excluded, which may have underestimated the effect of platelet transfusions on bleeding outcomes. platelet dysfunction due to anti-platelet medications or bypass circuits is common. A platelet transfusion study in that population would need to consider these other bleeding risks in addition to absolute platelet count levels for study entry.
These results contribute to the modest information base in transfusion medicine relevant to the care of critically ill patients. In this setting, most platelet transfusions were administered to prevent rather than to treat bleeding; however, the effect of this intervention on bleeding avoidance and other clinical endpoints remains uncertain. Our data emphasizes the need for randomized trials of platelet transfusions in the ICU. Cook conceived the research, collected the data, analyzed the data, interpreted the results and wrote the manuscript.
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